This event is in the past.
San Diego BioProcess Forum
Cordially Invites You to our Last 2012 Meeting.
Featuring a presentation by:
Chad Green, Ph.D.
Director, Device Engineering and Manufacturing, Viacyte
“Developing a Encapsulated Stem Cell-Derived Therapy for Diabetes”
ViaCyte is a preclinical therapeutic company focused on diabetes with a goal of providing insulin independence on a long-term basis, while reducing or eliminating hypoglycemic, microvasculature, and weight-related cardiovascular complications. Our therapy is based on the differentiation of stem cells into pancreatic beta cell precursors followed by subcutaneous implantation in an encapsulation device. This device, known as the Encaptra® Drug Delivery System, is retrievable, non-biodegradable, biocompatible and protects against allorejection such that the implanted pancreatic progenitor cells survive and differentiate into functioning islet cells capable of producing insulin in response to glucose. Using current data, this presentation will review the Encaptra® Drug Delivery System and ViaCyte’s recent progress towards the development of a stem cell-derived combination product to treat diabetes.
Please RSVP to reserve your space.
Membership and Event admission are FREE.
Go to "Upcoming Events" page on www.sdbioprocessforum.org to RSVP.
We may share participants' information with our sponsors. By registering for this event, you agree to these terms.
Wednesday November 14, 2012
5:30PM – 7:30PM
Presentation at 6:30PM
Sheppard Mullin LLP
12275 El Camino Real, Suite 200
San Diego CA 92130
Food, beverages, and venue provided by our sponsors: